In MM, ibrutinib was shown to decrease CXCL12-mediated migration, down-modulate CCL3, and affect MM cell growth and survival triggered by IL6 or contact with stromal cells [32, 33]. Here, CXCL12 is linked to Miyoshi myopathy.